TickerFacts.

Anbio Biotechnology (NNNN): Gross Profit

Annual figures by period end, from SEC filings.

$7.54M
Year ended 2025-12-31
-15.6%
3-year compound annual growth
$12.56M2022-12-31: $12.56M2023-12-31: $3.36M2024-12-31: $5.89M2025-12-31: $7.54M$7.54M
2022-12-31 Gross Profit (USD) 2025-12-31
Period endedGross ProfitChange YoYSource filing
2025-12-31$7.54M+28.2%2026-04-07, From 2025-01-01
2024-12-31$5.89M+75.1%2026-04-07, From 2024-01-01
2023-12-31$3.36M-73.2%2026-04-07, From 2023-01-01
2022-12-31$12.56Mn/a2025-04-28, From 2022-01-01

Gross Profit at similar companies

Companies with the same SEC industry code (In Vitro & In Vivo Diagnostic Substances), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedGross ProfitChange YoY
Anbio Biotechnology (NNNN)2025-12-31$7.54M+28.2%
Aspira Women's Health Inc. (AWHL)2025-12-31$5.92M+8.0%
Biomerica Inc (BMRA)2026-05-31$362.0K-27.3%
Insight Molecular Diagnostics Inc. (IMDX)2025-12-31$2.30M+210.5%
Immucell Corp (ICCC)2025-12-31$11.45M+44.1%
Alpha Teknova, Inc. (TKNO)2025-12-31$13.44M+85.9%
Celldex Therapeutics, Inc. (CLDX)2025-12-31$1.34Mn/a
Myriad Genetics Inc (MYGN)2025-12-31$576.60M-1.5%
Neogen Corp (NEOG)2026-05-31$408.50M-3.1%

Compare NNNN, AWHL, BMRA, IMDX side by side · Screen every company in In Vitro & In Vivo Diagnostic Substances ↗